摘要
为识别、区分以及明确人体内各部位微生物组的生物学功能, 美国国立卫生研究院于2007年发起了人体微生物组学研究计划。经过10余年推进, 该计划显著提升了人们对包括呼吸道在内的多个微生物组学与健康、疾病间关系的认识, 纠正了"下呼吸道无菌状态"观念。正常情况下微生物群体通过内部相互制约以及与宿主的相互作用, 使微生物和宿主处于共同受益状态, 打破该平衡则导致疾病发生、发展。慢性气道疾病是常见的慢性疾病, 以慢性阻塞性肺疾病和哮喘为代表的慢性气道疾病是我国最为常见、疾病负担最为严重的慢性疾病。本文罗列了多种慢性呼吸道疾病背景下气道肺微生物组学的变化特点, 以及"肠-呼吸道微生物轴"相互作用, 并探讨以调控肺微生物组学为切入点, 开发呼吸慢病新型治疗药物及方法的可能性。
In order to identify,distinguish,and clarify the biological function of microbiome in various organs of the human body,the US National Institutes of Health launched the human microbiome program in 2007.After more than 10 years of promotion,this project improved people′s understanding of the relationship between microbiome and the body significantly,including respiratory tract,and broke the fallacy of the"lower respiratory tract is sterile".Under normal circumstances,microbial community benefits from the interaction between the microorganism and the host.Chronic airway disease,a common chronic disease,represented by chronic obstructive pulmonary disease and asthma is the most common and most serious chronic disease in China.This paper lists the characteristics of microbiome in the respiratory tract and the lung in the background of various chronic respiratory diseases,and the importance of host respiratory tract microbiome interaction is expounded.Furthermore,we discussed the possibility of developing new therapeutic drugs and methods for the chronic respiratory diseases by regulating lung microbiome.
作者
张思源
屈朔瑶
Zhang Siyuan;Qu Shuoyao(Department of Pulmonary and Critical Care Medicine,the First Affiliated Hospital,Airforce Military Medical University,Xi′an 710032,China)
出处
《国际呼吸杂志》
2022年第10期785-789,共5页
International Journal of Respiration
基金
国家自然科学基金(82070029)。
关键词
慢性呼吸道疾病
微生物组学
肺肠轴
研究进展
Chronic respiratory diseases
Microbiome
Lung-gut axis
Research progress
